Connect with us

Medicine and Health

The first patient in England has received an mRNA vaccine for bowel cancer, with thousands more expected to receive it in the future

blank

Published

on

blank

Today, there is promising news for cancer patients in England, as a large number of individuals will be expedited onto a novel program that will grant them the opportunity to receive experimental personalized vaccines. The Cancer Vaccine Launch Pad initiative seeks to increase the number of patients participating in trials for mRNA vaccines targeting their specific type of cancer. The objective is to expedite the development of these potentially transformative treatments.

Elliot Phebve, a 55-year-old university lecturer and father-of-four who was diagnosed with colorectal cancer following routine testing, was the inaugural recipient of a vaccination under the new program. Phebve is currently receiving chemotherapy treatment and has also been invited to participate in a clinical trial following surgery to remove the tumor and a portion of the intestine.

Participating in this trial aligns with my occupation as an educator and my commitment to community involvement. Phebve expressed her desire to have a positive influence on the lives of others and assist them in recognizing their full potential,” stated Phebve.

Phebve received the experimental vaccine at a hospital that is part of a program called the Cancer Vaccine Launch Pad, which includes 30 hospitals in England. Additional hospitals are expected to join the program in the near future.

The COVID-19 pandemic has demonstrated the potential of mRNA vaccine technology. However, the significant advantage of these vaccines in the context of cancer is their ability to be tailored to a particular tumor in an individual patient, thereby maximizing their efficacy. A significant Phase 3 trial of a melanoma vaccine was recently initiated, and soon after, there were reports of promising preliminary outcomes of a brain cancer vaccine in both humans and dogs, our loyal companions.

The Cancer Vaccine Launch Pad aims to enhance patient access to this innovative technology by simplifying the process of evaluating eligibility and inviting patients to participate in a suitable trial.

“The NHS, being the UK’s National Health Service, has the advantage of being able to conduct large-scale and groundbreaking research. As more of these trials are initiated in hospitals throughout the country, our national matchmaking service will ensure that as many eligible patients as possible have the opportunity to participate,” clarified Amanda Pritchard, the CEO of the NHS.

An mRNA vaccine aims to stimulate a patient’s immune system to generate antibodies against specific proteins that are implicated in their cancer. This knowledge is acquired through the examination of tumor tissue. When administered alongside surgery, radiotherapy, and other pharmacological interventions, as determined by oncologists, these vaccines are expected to aid in the elimination of any remaining tumor cells in the body and decrease the likelihood of the cancer returning.

Iain Foulkes, the Executive Director of Research and Innovation at Cancer Research UK, emphasized the crucial role of clinical trials in improving the longevity and quality of life for individuals by alleviating the burden of cancer.

The UK government is collaborating with vaccine manufacturer BioNTech, committing to deliver precision cancer treatment to 10,000 patients by 2030. There are plans to expand the program to include other types of cancer, such as pancreatic cancer. Pancreatic cancer is the 10th most prevalent type of cancer in the UK, but it is the fifth leading cause of cancer-related deaths.

The development of cancer vaccines is becoming increasingly feasible, owing to a series of significant advancements and favorable outcomes in clinical trials. Phebve succinctly described the potential impact of a novel treatment option on the approximately 50% of individuals who are expected to experience cancer during their lifespans.

“If this trial is successful, it has the potential to benefit thousands, if not millions, of individuals, providing them with hope and potentially preventing them from enduring the same hardships I have.” I anticipate that this will be beneficial to others.

As Editor here at GeekReply, I'm a big fan of all things Geeky. Most of my contributions to the site are technology related, but I'm also a big fan of video games. My genres of choice include RPGs, MMOs, Grand Strategy, and Simulation. If I'm not chasing after the latest gear on my MMO of choice, I'm here at GeekReply reporting on the latest in Geek culture.

Medicine and Health

A recently identified strain of deadly fungus poses a significant risk to public health

blank

Published

on

blank

Researchers have recently discovered a new group of Candida auris, a potentially dangerous pathogen. The finding increases the total number of identified clades of the fungus, which is a newly emerging superbug resistant to multiple drugs, to six.

Candida auris is a strain of yeast that has the potential to cause serious illness and is frequently impervious to antifungal drugs. While individuals who are in good health generally do not fall ill, the transmission of the disease is highly prevalent within medical institutions and poses a significant risk to individuals with compromised immune systems. The yeast can induce a variety of conditions ranging from superficial infections of the skin to more severe and life-threatening illnesses, such as bloodstream infections. Due to its high level of resistance to multiple drugs, treating it can be challenging, and in some cases, even impossible.

The authors state that the pathogen is a significant global public health threat due to its widespread distribution, resistance to multiple drugs, high ability to spread, tendency to cause outbreaks, and high mortality rate. Although infections are still relatively uncommon, there has been a significant increase in cases in recent years.

Previously, the fungus had been categorized into five distinct clades, each located in different geographic regions: South Asia, East Asia, Africa, South America, and Iran.

In April 2023, doctors from the Singapore General Hospital identified a patient carrying a unique strain of C. auris as part of a routine screening program, adding it as the most recent clade to be discovered. Typically, these cases arise from individuals who have recently traveled, but this particular patient had not traveled outside the country for a period of two years, which raised some concerns.

Upon conducting a genetic analysis of the strain, the researchers determined that it did not align with any of the five known clades of the fungus. Therefore, it can be concluded that the strain belongs to a previously unidentified, sixth clade. Subsequently, they conducted tests on strains obtained from previous patients and identified two additional isolates of this particular group of C. auris in Singapore, as well as another isolate in Bangladesh.

The extent of the new clade’s prevalence and its potential to cause invasive infections and outbreaks remains uncertain at present. However, the researchers emphasize the importance of promptly identifying and controlling it in order to safeguard patient well-being.

“The ramifications of this breakthrough transcend the confines of the laboratory.” “Given the recent discovery of the sixth Candida auris clade, it is imperative to enhance surveillance capability or create new methods to strengthen existing surveillance strategies. This will enable health care facilities to closely monitor its emergence and effectively control its spread,” stated Dr. Karrie Ko, co-first author of the study.

Fortunately, the cases described in the study remained vulnerable to all antifungals that were tested. This should alleviate concerns about a pandemic similar to the one depicted in The Last Of Us. However, it is evident that the threat of C. auris is persistent. Therefore, additional efforts are required to identify new strains, monitor their spread, and control any negative clinical consequences.

The research is published in The Lancet Microbe journal.

Continue Reading

Medicine and Health

What makes your chest hurt when something makes you jump?

blank

Published

on

blank

Have you ever been scared so badly that you grabbed your chest? You feel like someone or something just zapped you behind the sternum. As you rest, you lean against the wall and think about why your friend is such a jerk and why you can feel it in your chest whenever you get scared.

People often use words like “heart-stopping” when they write fiction about fear, but the science of fear tells us that this isn’t what’s happening because it wouldn’t make sense. Our bodies are getting ready to deal with an impending threat when we’re scared, and going into cardiac arrest wouldn’t help us get very far if a lion was after us.

What do we do when we’re scared?
The sympathetic nervous system is what gets you excited when something makes you jump. It’s a tool inside our bodies that releases hormones and changes the way our bodies work to get us ready for the fight-or-flight response.

One important part is adrenaline, which is also known as epinephrine. The adrenal glands squeeze it out into the blood. The heart starts beating faster, sending more blood to your muscles and organs right away. Because they need all the oxygen they can get if they want to get away from a dangerous animal.

How do you feel when you go for a run?
Anyone who has ever used an EpiPen knows how bad it is to feel a sudden rush of adrenaline. It’s a stress hormone that makes you feel nervous and anxious, like you would before doing a bungee jump. Getting a rush when you think about a traumatic event from the past can be a sign of PTSD.

A medicine called adrenaline is used because it can help people who are having a medical emergency. If you have anaphylaxis from an allergen like peanuts, this can help because it can open your airway. Because it changes the strength and speed of heartbeats, it is also sometimes used to help people who are having a cardiac arrest.

When your adrenaline level goes up quickly, you may feel shaky, your heart beat quickly, and your chest get tight. When you add in the fact that you’re more alert, you become very aware of the changes in your body. This is especially clear when you’re not in danger, like when your partner surprised you at home when you thought you were alone.

When you’re scared, your sympathetic nervous system usually kicks in, which is normal. But, some heart conditions can get worse when you’re scared. Should anyone be having chest pain or ongoing discomfort, they should see a doctor. In the end, it is possible to be so scared that you die.

This article is not meant to be a replacement for medical advice, diagnosis, or treatment from a trained professional. If you have questions about a medical condition, you should always talk to a qualified health professional.

Continue Reading

Medicine and Health

The Lacks family is suing again over her “stolen” cells

blank

Published

on

blank

The family of Henrietta Lacks has filed a new lawsuit against two sizable drug companies for using her genetic material without her consent.
In the US District Court for the District of Maryland, Lacks’ living relatives are suing Novartis Pharmaceuticals Corporation, Novartis Gene Therapies, Inc., Viatris, Inc., and its subsidiary, Mylan Pharmaceuticals. They say the companies have used the “stolen” HeLa cell line to make hundreds of patents and have made a lot of money from it.

The suit wants the money made from using these cells to be “rightfully transferred” to Henrietta Lacks’s estate.

Novartis and Viatris chose to sell Henrietta Lacks’ living genetic material. Lacks was a black grandmother, community leader, and woman whose doctors took her tissue without her knowledge or permission, according to Chris Ayers, an attorney at Seeger Weiss LLP who is representing the Lacks family.
Ayers added, “We will keep looking for justice for Mrs. Lacks and her family.”

Henrietta Lacks died on October 4, 1951, from cervical cancer. She was 31 years old. Some of her cells are still alive today. A doctor at Johns Hopkins Hospital took a sample of her cervical cells without her knowledge just before she died. They were doing a cancer check. It was seen that her cells kept multiplying quickly, even after most of the cells in other samples would have died without their host.

Because scientists saw the potential, they found that these cells could be a cheap and easy way to help researchers do more research. The “HeLa immortal cell line” is what scientists call these cells, and they are very useful for biomedical research.

Over 75,000 scientific studies around the world have used these cells, which amount to about 55 million tons. They have been very important in making progress in areas like polio vaccines, cancer treatments, HIV/AIDS treatments, and much more.

All of this was done, though, without Lacks’ knowledge or permission. For many years, her family also didn’t know that the cells were being used for business.
Selling HeLa cells for money brings up important issues in medical ethics and genetics. As a black woman living in America in the 1950s, Lacks’ case shows how medical racism still affects minorities who aren’t getting enough help.

Even though a lot of people know about these problems, HeLa cells are still used in medical research for profit, which makes some companies a lot of money.
“Now that everyone knows Henrietta Lacks’ story, it’s shocking, but not surprising, that drug companies like Novartis and Viatris are still making money off of the deeply unethical origins of HeLa cells and the disturbing history of medical racism,” said Chris Seeger, another lawyer for the family.

A historic deal was made by Lacks’ family in 2023 after they sued Thermo Fisher Scientific, Inc., another biotech company, in the US District Court for the District of Baltimore. During that time, the lawyers said that the settlement was only the beginning and that there could be many more lawsuits about the use of HeLa cells.

Continue Reading

Trending